Vitals Knowledge Vault

Gingipain

3 min read

Gingipain

TL;DR: Gingipains (RgpA/B arginine-specific and Kgp lysine-specific) are secreted cysteine proteases from Porphyromonas gingivalis. They are the organism’s primary virulence factors and can directly cleave human tau protein at dozens of sites, degrade tight junction proteins, activate complement, and trigger neuroinflammation. However, the COR388 gingipain-inhibitor trial failed in AD patients, gingipains are detected in neurologically normal aging brains, and no causal link to human AD has been established.

Overview

Gingipains are a family of secreted cysteine proteases produced exclusively by P. gingivalis:

EnzymeSpecificityGeneLocation
RgpAArg-specific (cleaves after Arg)rgpACell-associated + secreted
RgpBArg-specificrgpBCell-associated
KgpLys-specific (cleaves after Lys)kgpCell-associated + secreted

Rgp = arginine gingipain; Kgp = lysine gingipain. Both are secreted as soluble enzymes or as surface-attached complexes with hemoglobin-binding domains (HmuY, Hgp44, Hgp27).

Key Actions

Tau Cleavage

Mass spectrometry identified 44 combined cleavage sites for Kgp (30 sites) and RgpB (14 sites) across tau-441 (PMID:30746447):

  • Kgp cleaves at VQIVYK (tau microtubule-binding repeat domain — PHF nucleation site) and VQIINK sequences
  • RgpB cleaves at TPSLPTPPTR (residues 212–221, Tau-5 epitope region — loss of Tau-5 immunoreactivity in infected cells)
  • At 1 nM gingipain: 23% of tau-441 fragmented; at 10 nM: 85% fragmented

This is the primary mechanistic argument for P. gingivalis in AD tau pathology.

Blood-Brain Barrier Permeability

RgpA activates the Ddx3x/Mfsd2a/Cav-1 axis in brain microvascular endothelial cells (PMID:38414291):

  • RgpA suppresses Mfsd2a (the BBB transcytosis gatekeeper) and upregulates Cav-1
  • This enhances caveolae-mediated transcytosis across the BBB
  • Effect observed in vitro and in mouse models

Complement Activation

Gingipains activate the complement system directly (C3/C5 cleavage) and by degrading complement regulators (C1-inhibitor, factor H). This creates a pro-inflammatory local environment in periodontal tissue and potentially systemically.

Fibrinogen and Hemostasis

Gingipain cleavage of fibrinogen produces fragments that promote abnormal fibrin deposits in blood vessels — hypothesized to contribute to cerebral small vessel disease and impaired blood flow in AD.

Clinical Relevance

Therapeutic targeting:

  • COR388 (atuzaginstat) — dual Rgp/Kgp inhibitor; entered Phase 2 for AD (NCT03823404)
  • COR271 — Kgp-selective inhibitor; 90% reduction in brain bacterial load in mice (PMID:30746447); not advanced to human trials

COR388 Phase 2 failure (n=643, 48 weeks):

  • Primary endpoints: ADAS-Cog 11 and ADCS-ADL — not met
  • Target engagement confirmed (reduced anti-P. gingivalis IgG)
  • 40% dropout; 4 deaths in 80 mg arm
  • Company (Cortexyme) filed Chapter 11 in August 2023
  • Key implication: even with confirmed gingipain inhibition and target engagement, no cognitive benefit was observed

Limitations

  1. Not disease-specific: Ermini et al. 2024 (PMID:38664405) detected gingipains in both PD and neurologically normal control brains
  2. COR388 failure: Demonstrates that gingipain inhibition without bacterial clearance does not improve cognitive outcomes in established AD
  3. Independent replication gap: Most prominent studies are from Cortexyme-affiliated researchers; fully independent replication is limited
  4. Consequence vs. cause: Gingipain presence may be a consequence of BBB breakdown in neurodegeneration, not its cause

Vitals Relevance

  • Inflammatory biomarker confound: Gingipain-driven complement activation and IL-6/TNF-α elevation may chronically raise CRP/IL-6 baselines
  • Recovery tracking: Unexplained inflammatory elevations in individuals with poor oral health may reflect periodontitis rather than training load
  • No direct wearable detection: Gingipain activity cannot be detected from consumer wearable devices

References

  • PMID:30746447 — Dominy et al. 2019, Sci Adv (tau cleavage, full mechanism)
  • PMID:38414291 — BBB permeability / Ddx3x/Mfsd2a/Cav-1 axis
  • PMID:38664405 — Ermini et al. 2024, NPJ Parkinsons Dis (gingipains in normal brains)
  • NCT03823404 — COR388 Phase 2 (GAIN trial — negative)
  • PMID:31999052 — Arastu-Kapur et al. 2020, Pharmacol Res Perspect (dog study)

Graph View

Backlinks